A Comprehensive COVID-19 Treatments Review

By Staff Writer

October 20, 2023

COVID-19 Treatments: A Race Against Time

The COVID-19 pandemic has led to an urgent need for effective treatments of this unknown disease. As of January 2023, there have been over 620 million confirmed cases of the virus and more than six-and-a-half million deaths worldwide. In the UK alone, the numbers are staggering with more than 24 million cases and nearly 200,000 deaths during this time.

COVID-19 Treatments Review

Various treatments have been developed and used to help people who have been hospitalised due to COVID-19 or are at high risk of needing hospitalisation. These include casirivimab/imdevimab, tocilizumab, remdesivir, baricitinib, and baricitinib with remdesivir for hospitalised patients. For patients at high risk, treatments include casirivimab/imdevimab, molnupiravir, nirmatrelvir/ritonavir, remdesivir, sotrovimab, and tixagevimab/cilgavimab.

Evaluating Clinical Efficacy and Cost-effectiveness

The objective of this study was to summarise the current knowledge related to the clinical efficacy of these interventions and to conduct an economic evaluation that estimates the cost-effectiveness of each intervention against standard of care (SoC).

Despite the urgency, these treatments have not received positive guidance from the National Institute of Health and Care Excellence (NICE) before being routinely used. As the pandemic subsides, there is more need for a formal evaluation of these treatments.

The results of the study, however, should be treated with caution due to changes in the conditions when the pivotal studies were undertaken and the current conditions in terms of the SoC, the percentage of people who have been vaccinated and a change in the dominant SARS-CoV-2 variant.

Reference url

Recent Posts

modifiable risk factors
        

Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression

🧠 What if addressing just a few key lifestyle factors could significantly reduce the risk of stroke, dementia, and depression in older adults?

A recent systematic review has identified 17 **modifiable risk factors**, revealing the interconnected nature of these age-related brain diseases and offering crucial insights for preventive strategies. By focusing on aspects such as blood pressure management, nutrition, and physical activity, we can enhance quality of life for our aging population.

Dive into the article to explore how these findings could shape future healthcare models.

#SyenzaNews #HealthEconomics #HealthcareInnovation #DigitalTransformation

drug price regulation
      

Navigating Drug Price Regulation: Evaluating the Executive Order’s Potential Impacts and Challenges

💊 Curious about the future of drug pricing in the U.S.?

The recent executive order aims to tackle escalating prescription drug costs through measures like international reference pricing and enhanced transparency. However, the implications of these policies could be more complex than anticipated, with potential risks to market access and innovation.

Dive into the article for a detailed analysis of how these regulations could shape the pharmaceutical landscape and what it means for healthcare access in the U.S.

#SyenzaNews #pharmaceuticals #healthcarepolicy

AI Patient Education
       

AI Patient Education: Evaluating ChatGPT and Gemini for Pediatric Condition Materials

🤔 Are AI solutions ready to revolutionize pediatric patient education?

A recent study compared ChatGPT and Gemini in generating educational materials for common pediatric conditions, revealing intriguing insights into content depth, readability, and reliability. While both tools have their merits, there’s significant room for improvement in making AI-generated content accessible and effective for all families.

Curious to learn more about the implications for health literacy and the future of AI in healthcare? Click to read the full article!

#SyenzaNews #AIinHealthcare #HealthTech #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.